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Abstract
Background: Carbapenem-resistant Acinetobacter baumannii poses a significant threat to hospitalized patients, as
few therapeutic options remain. Thus, we investigated the molecular epidemiology and mechanism of resistance
of carbapenem-resistant A.baumannii isolates in Beijing, China.
Methods: Carbapenem-resistant A.baumannii isolates (n = 101) obtained between June 2009 and November 2014
were used. Multilocus sequence typing (MLST) and PCR assays for class C and D β-lactamase were performed on all
isolates. S1 nuclease pulsed-field gel electrophoresis (PFGE) and Southern blot hybridization were performed to
identify the resistance gene location.
Results: All 101 A.baumannii isolates were highly resistant to frequently used antimicrobials, and were considered
multidrug resistant. A total of 12 sequence types (STs) were identified, including 10 reported STs and 2 novel STs.
Eighty-seven isolates were classified to clonal complex 92 (CC92), among which ST191 and ST195 were the most
common STs. The blaOXA-23 gene was positive in most (n = 95) of the A.baumannii isolates. Using S1-nuclease
digestion PFGE and Southern blot hybridization, 3 patterns of plasmids carrying blaOXA-23 were confirmed. ST191
and ST195 (both harboring blaOXA-23) caused outbreaks during the study period, and this is the first report of
outbreaks caused by ST191 and ST195 in north China.
Conclusion: blaOXA-23-producing A.baumannii ST191 and ST 195 isolates can disseminate in a hospital and are
potential nosocomial outbreak strains. Surveillance of imipenem-resistant A.baumannii and antimicrobial
stewardship should be strengthened.
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Background
Acinetobacter baumannii is an opportunistic pathogen
involved in outbreaks occurring in burn units, surgical
wards or intensive care units (ICUs), as well as import-
ant cause of nosocomial septicemia, pneumonia and
urinary tract infections [1]. A.baumannii is of interest
due to increasing the increase in antimicrobial resistance
[2]. This organism is generally intrinsically resistant to
many frequently-used antibiotics, including aminopeni-
cillin, first- and second-generation cephalosporins and
chloramphenicol [3, 4]. Carbapenems are important an-
tibiotics to treat A.baumannii because they are highly
efficacious and have low toxicity [5]. However, the emer-
gent and rapid spread of carbapenem-resistant A.bau-
mannii isolates pose a severe threat to public health and
are a global concern [6]. Carbapenem resistance, such
as to imipenem, increased in China from 31.0% in
2005 to 62.4% in 2014 [7]. Recent studies also suggest
high resistant of A.baumannii against carbapenems
across the world [8–11].
Carbapenem resistance in A.baumannii is mainly me-
diated by the production of carbapenem-hydrolyzing
enzymes [6]. Class D OXA-type enzymes are the most
prevalent carbapenemases in A.baumannii [12]. In
addition to the intrinsic OXA-51-like enzymes, 3 unre-
lated groups of these carbapenem-hydrolysing enzymes
have been identified OXA-23-like, -40-like and -58-like
[13]. Outbreaks of blaOXA-23-producing A.baumannii have
been reported across the world [14–16] and a previously
study has pointed out that blaOXA-23 was the predominant
group of carbapenem-hydrolysing enzymes in China [17].
Multilocus sequence typing (MLST) is used for global
and long-term epidemiological studies [18], and data from
MLST show that CC92 was the most widely distributed
A.baumannii clone globally [19–21]. Studies from China
indicate that blaOXA-23-producing CC92clones are preva-
lent in most provinces of China [17, 22]. Although the mo-
lecular epidemiology of carbapenem-resistant A.baumannii
has been investigated, the epidemiology of carbapenem-
resistant A.baumannii over long time periods in single
institution may allow new insights into the behavior
of this pathogen.
Thus, we sought to investigate carbapenem-
resistance mechanisms and the molecular epidemi-
ology of carbapenem-resistant A. baumannii in a
single hospital over a 65-month period.
Methods
Bacterial isolates
Between June 2009 and November 2014, a total of 101
nonduplicate carbapenem-resistant (Zone Diameter of
imipenem ≤18 mm; Clinical Laboratory Standards Insti-
tute [CLSI] breakpoint) A. baumannii (CRAB) isolates
were collected from a single hospital in Beijing, China. A
single isolate per patient was included. All isolates were
identified by conventional biochemical techniques using
VITEK 2 system (BioMérieux France). PCR confirmation
of the blaOXA-51-like carbapenemase gene was performed
to help identify A. baumannii simultaneously, because
this gene is intrinsic to A. baumannii [23, 24].
Antimicrobial susceptibility testing
The disk diffusion method was used to evaluate suscep-
tibility to the following antimicrobial agents: imipenem
(IPM: 10 μg), ceftazidime (CAZ: 30 μg), amikacin (AMK:
30 μg), piperacillin/tazobactam (TZP: 100/10 μg), levo-
floxacin (LVX: 5 μg), ticarcillin/Clavulanic acid (TCC:
75/10 μg), minocycline (MNO: 30 μg) (Oxoid, UK). Re-
sults were interpreted in accordance with CLSI guide-
lines from 2011. Isolates with intermediate susceptibility
were classified as non-susceptible.
Molecular typing methods
Multilocus sequence typing (MLST) was performed on
all A.baumannii isolates as described previously [18].
Analysis of allele sequences and sequence type (ST) as-
signment made use of the Oxford Acinetobacter bau-
mannii MLST website (http://pubmlst.org/abaumannii/).
The eBURST algorithm (version 3; http://eburst.mlst.
net/) was used to assign clonal complexes (CCs).
Screening of ambler classes C and D β-lactamase genes
PCR experiments were carried out using primers specific
for the genes encoding Ambler C and D β-lactamase
(AmpC, MOX-1, MOX-2, CMY-1 to CMY-11, BIL-1,
DHA-1, DHA-2, ACC, ACT-1, MIR-1 T, FOX-1 to
FOX-5b, blaOXA-23-like, blaOXA-40-like, blaOXA-51-like, and
blaOXA-58-like and blaOXA-143)as described previously
[25–28]. Primers are depicted in Table 1. For each gene
detected, some PCR products were randomly selected,
and then sequenced to confirm genes.
PFGE and Southern blot hybridization
To detect plasmids of A.baumannii isolates, an agarose
gel plug containing total cellular DNA was prepared and
digested with S1 nuclease (Takara, Japan) as described
previously [29]. Digested plugs were subjected to PFGE
using a CHEF-Mapper system (pulse times, 5 to 30 s;
running time, 15 h; 6 V/cm). Gels were blotted onto nylon
membranes (Millipore, USA) using standard techniques.
The membrane was hybridized with a digoxigenin-labeled
probe consisting of a blaOXA-23 fragment which was ampli-
fied by primers.
Results
A total of 101 A.baumannii isolates were resistant to
imipenem and considered carbapenem-resistant and en-
rolled in our study. CRAB isolates were obtained from
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various sources, including sputum (n = 72 isolates),
blood (n = 14 isolates), abdominal fluid (n = 9 isolates),
secretion (n = 2 isolates), catheter (n = 1 isolates), eyes
(n = 1 isolates), pus (n = 1 isolates) and throat swabs
(n = 1 isolates). Of 101 CRAB isolates, 87% (n = 88)
were collected from the ICU. The temporal distribution of
CRAB isolates is showed as follows. 2, 3, 45, 4, 18 and 29
isolates were obtained in 2009, 2010, 2011, 2012, 2013 and
2014, respectively. CRAB isolates resistance data appear in
Table 2. All CRAB isolates were resistant to at least 3 clas-
ses of antibiotic and were considered multidrug resistant.
CRAB isolate data for AmpC and blaOXA-51-like genes
appear in Table 2.
To investigate the molecular epidemiology of isolates,
MLST was performed to characterize CRABs and data
are summarized in Table 2. The eBURST analysis data
appear in Fig. 1.
ST191 was the largest sequence type (32 of 101 isolates)
and was found in our institution from August 2009 to
May 2012. Only 1 isolate was obtained in August 2009
from the Liver Failure ward, but most (96.9%) of ST191
isolates were collected between February 2011 and May
2012. Importantly, 28 of the 32 ST191 strains were
isolated from ICU ward. All ST191 isolates were resistant
to piperacillin/tazobactam, ticarcillin/clavulanic acid, cef-
tazidime and levofloxacin but had variable susceptibilities
to amikacin and minocycline (Table 2). All of ST191 iso-
lates were blaOXA-23-positive. One strain was selected
randomly to be subjected to PFGE digested with S1 nucle-
ase, and results show that this ST strain contains a
plasmid of approximately 78 Kb. Southern blot hybrid
hybridization assays confirmed that blaOXA-23 gene was
located on this plasmid (Fig. 2).
Thirty-one (30.7%) isolates were defined as ST195,
and this ST was first detected in the infectious liver
diseases ward in March 2013. Twenty-eight ST195
isolates were collected from ICU ward from then on.
It is notable that all ST195 isolates were resistant to
almost all antibiotics tested in this study except 1 iso-
late was susceptible to amikacin. All of ST195 isolates
were also blaOXA-23 positive. This ST strain does not
contain any plasmid, and the blaOXA-23 gene is located on
the chromosome (Fig. 2).
Another 4 sequence types, ST208, ST368, ST218 and
ST369, were found in 15 (14.8%), 6 (5.9%), 2 (2.0%) and
1 (1.0%) isolates, respectively, and carried the blaOXA−23
Table 1 Primers used in this study
Primer Sequence(5′ to 3′) Target Reference








DHAMF AACTTTCACAGGTGTGCTGGGT DHA-1, DHA-2 [25]
DHAMR CCGTACGCATACTGGCTTTGC
ACCMF AACAGCCTCAGCAGCCGGTTA ACC [25]
ACCMR TTCGCCGCAATCATCCCTAGC
EBCMF TCGGTAAAGCCGATGTTGCGG MIR-1 T ACT-1 [25]
EBCMR CTTCCACTGCGGCTGCCAGTT
FOXMF AACATGGGGTATCAGGGAGATG FOX-1 to FOX-5b [25]
FOXMR CAAAGCGCGTAACCGGATTGG
AmpCF ACAGAGGAGCTAATCATGCG AmpC [26]
AmpCR GTTCTTTTAAACCATATACC
OXA-23-likeF GATCGGATTGGAGAACCAGA' blaOXA-23-like [27]
OXA-23-likeR ATTTCTGACCGCATTTCCAT
OXA-40-likeF GGTTAGTTGGCCCCCTTAAA blaOXA-40-like [27]
OXA-40-likeR AGTTGAGCGAAAAGGGGATT
OXA-51-likeF TAATGCTTTGATCGGCCTTG blaOXA-51-like [27]
OXA-51-likeR TGGATTGCACTTCATCTTGG
OXA-58-likeF AAGTATTGGGGCTTGTGCTG blaOXA-58-like [27]
OXA-58-likeR CCCCTCTGCGCTCTACATAC
OXA-143 TGGCACTTTCAGCAGTTCCT blaOXA-143 [28]
OXA-143 TAATCTTGAGGGGGCCAACC
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gene but had different resistance profiles. The blaOXA−23
gene is located on the plasmid in the A.baumannii
ST218 and ST368 strain, but is found on the chromo-
some in ST208 and ST369.
Six isolates were ST469. This is a double-locus variant
(DLV) of multiple STs within CC92, implying a close rela-
tionship. However, it does not agree with the conservative
definition of sharing alleles at 6/7 of the loci, and thus
ST469 cannot be considered a CC92 member. All ST469
isolates were collected during December 2012 and
November 2013. ST469 isolates were blaOXA-23 positive
and were resistant to allantibiotics. PFGE and hybridization
results show that this ST isolate harbored 2 plasmids. The
blaOXA-23 gene was located on a ca. 120 kb plasmid and on
a plasmid of approximately 245 kb, with another copy of
blaOXA-23 on a chromosome (Fig. 2).
Two unreported singleton STs were identified. ST1309
presented in this hospital in August 2011 only and was
Table 2 Details of A. baumannii isolates, by sequence type
Non-susceptible to (%): Resistant determinants
ST No. Allelic profile Time course IPM TZP TCC CAZ AMK LVX MNO
191 32 1-3-3-2-2-94-3 Aug. 2009
Feb. 2011–May. 2012
100 100 100 100 38 100 23 OXA-51, OXA-23, AMPC
195 31 1-3-3-2-2-96-3 Mar. 2013–Nov. 2014 100 100 100 100 97 100 100 OXA-51, OXA-23, AMPC
208 15 1-3-3-2-2-97-3 Jul. 2010–Oct. 2014 100 100 100 93 100 100 100 OXA-51, OXA-23, AMPC
218 2 1-3-3-2-2-102-3 Jul. 2011–Aug. 2011 100 100 100 100 100 100 0 OXA-51, OXA-23, AmpC
368 6 1-3-3-2-2-140-3 Jun. 2009–Sep. 2014 100 100 100 100 67 67 33 OXA-51, OXA-23, AmpC
369 1 1-3-3-2-2-106-3 Jun. 2013 100 100 100 100 0 100 - OXA-51, OXA-23, AmpC
373 2 1-12-12-11-4-103-3 Mar. 2011, Apr. 2011 100 100 100 100 0 100 0 OXA-51, AmpC
383 2 1-12-56-1-4-149-45 Aug. 2011 100 100 100 100 100 100 100 OXA-51, AmpC
429 2 1-34-56-1-4-144-45 Jul. 2011, Sep. 2011 100 100 100 100 50 50 100 OXA-51, OXA-23, AmpC
469 6 1-12-3-2-2-103-3 Dec. 2012-Nov. 2013 100 100 100 100 100 100 100 OXA-51, OXA-23, AmpC
1302n 1 2-52-80-6-23-140-4 Jul. 2014 100 100 100 0 0 0 0 OXA-51, OXA-40, AmpC
1309n 1 27-155n-99-55-25 -270n-60 Aug. 2011 100 100 100 100 100 100 100 OXA-51, AmpC
Total 101 - Jun. 2009–Nov. 2014 100 100 100 98 80 96 68 -
nNovel; IPM imipenem, TZP piperacillin/tazobactam, TCC ticarcillin/clavulanic acid, CAZ ceftazidime, AMK amikacin, LVX levofloxacin, MNO minocycline
Fig. 1 eBURST results of 12 STs presented in this study. The 1309 STs in the entire A.baumannii MLST database were analyzed using the most
stringent definition (6/7 shared alleles). Four groups and 2 singletons that included STs found in our study are displayed as an eBURST diagram
together. Each circle represents an ST. STs in a group are considered to belong to same clonal complex. Blue STs are founders of corresponding
group. Red STs were found in this study. Circle size reflects the number of strains. Other ST labels have been removed for clarity
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resistant to all the 7 classes of antimicrobials. The
carbapenem-resistant determinant of this isolate remains
unclear. The ST1302 isolate was unique among imipenem-
resistant strains; it was ceftazidime, amikacin, levofloxacin
and minocycline susceptible and was the only isolate that
carried the blaOXA-40 gene.
Discussion
This study offers insight into the longitudinal evalu-
ation of the molecular epidemiology of carbapenem-
resistant A.baumannii in a single institution over a
65-month period.
The blaOXA-23 gene was positive in most (n = 95) of
the A.baumannii isolates in this institution. The first re-
port of this enzyme in A.baumannii was ARI-1, which
was identified in an isolate from Scotland collected in
1985 [30]. In 2000, enzyme sequence analysis (re-named
OXA-23) indicated that it was a member of the ambler
class D group of β-lactamases [31]. Since then, outbreaks
of OXA-23 carbapenemase-producing A.baumannii have
been reported all over the world [32–36]. Our finding
was consistent with other reports from China. Zhou’s
group investigated resistance determinants of 342
imipenem-resistant A.baumannii isolates which were
collected from 16 Chinese cities in 2005, and found that
most CRAB isolates contained the blaOXA-23 gene [37].
Recent studies confirm a high prevalence of the blaOXA-
23 gene in carbapenem-resistant A.baumannii in differ-
ent Chinese cities (80.6-100%) [38–40]. Southern blot-
ting revealed that the blaoxa-23 gene is plasmid-mediated
in some STs (ST191, ST218 and ST368), but chromo-
some borne in others (ST195, ST208, ST369 and
ST429). Chromosomal locations of blaoxa-23 make it less
likely for A.baumannii to lose caarbapenem resistance.
Investigation of OXA-23 producing A.baumannii iso-
lates collected from 28 hospitals in 18 provinces of
Fig. 2 Results of plasmid measurement and hybridization. a S1 nulcease digestion of total DNA of A.baumannii isolates was followed by PFGE. Plasmid
bands are shown as linearized fragments on the gel. For each A.baumannii ST, only one strain was selected randomly for this assay. b Southern blot
hybridization for the blaoxa-23 gene. Lane M, reference standard strain H9812 restricted with XbaI. MW are in KB
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China showed that OXA-23 was mainly located on a
ca.78-kb plasmid or on a chromosome [41].
We were concerned that A.baumanii isolates harbor-
ing the blaOXA-23 gene were multidrug resistant in our
study and had few antibiotic therapeutic options for
treating CRAB infection. Thus, controlling the spread of
blaOXA-23 producing A.baumannii is important.
We identified ST191, ST195, ST208, ST218, ST368
and ST369 as classified into CC92 which was the largest
and most widely distributed A.baumannii clone in China
[17]. CC92 represented the most epidemic CRAB STs in
this hospital, accounting for 86.1% of isolates in this
study. For blaOXA-23-producing CRAB of CC92, the abil-
ity to disseminate in a single institution for a long time
suggests that adaptation to the hospital environment
may be important for the success of A.baumannii.
It has been suggested that any clinical A.baumannii
isolates with resistance to multiple antibiotics can cause
a nosocomial outbreak [42]. We found that imipenem-
resistant A.baumannii of CC92, compared with other
clonal complexes, may be more prone to cause severe
outbreaks during long-term dissemination. Two out-
breaks of CRAB CC92 were observed in our institution.
Most ST191 isolates (31/32) were identified between
February 2011 and May 2012 in the ICU ward, suggest-
ing an outbreak of blaOXA-23-producing ST191. Deng’s
group has reported the prevalence of an A.baumannii
ST191 clone in a southern Chinese hospital [43]. To our
knowledge, this is the first identification of an outbreak
of blaOXA-23 harboring A.baumannii ST191 isolate in
north China. A second outbreak of blaOXA-23-producing
CRAB occurred in this ICU later. Thirty-one blaOXA-23-
producing ST195 isolates were also found in the ICU
between March 2013 and November 2014and this se-
quence type was more resistant to frequently-used anti-
microbial agents compared with ST191. ST195 has
frequently been identified in Asian countries, including
Japan, Vietnam, and Malaysia [44–46]. To our know-
ledge, Li’s group was first to identify ST195 in a teaching
hospital in Guangzhou, in southern China [47]. Since
then, ST195 clones has been identified in western and
eastern China [38, 48]. Here, we offer the first report of
an outbreak of blaOXA-23-producing ST195 in north
China, suggesting that ST195 has been successfully
disseminated in this country.
We collected no environmental strains from the work
place, so we lack surveillance for source identification,
which is a significant limitation of our study.
Conclusions
In summary, blaOXA-23-producing CC92 isolates were
prevalent in this hospital over a 65-month period. Succes-
sive outbreaks of ST191 and ST195 demonstrated that per-
sisting clinical carbapenem-resistant A.baumannii isolate
can cause a nosocomial outbreak. Periodic investigation
of molecular epidemiology and resistance determinant
of A.baumannii is necessary.
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